ABC.L Regulatory News (ABC)

7 Nov 2007 07:01

ABCAM Plc07 November 2007 For immediate release 7 November 2007 ABCAM PLC ("Abcam" or "the Company") Appointment of Chief Financial Officer Abcam plc (AIM: ABC), the rapidly growing bioscience company that marketsantibodies via its own online catalogue, is pleased to announce the appointmentas Chief Financial Officer of Jeffrey Iliffe, a highly experienced financeprofessional with a track record in the City, the healthcare industry and ine-commerce. Mr Iliffe, who has been working as a financial consultant at Abcamfor the past 4 months, will join the Company's Board on 20 November 2007. Mr Iliffe's appointment is the result of a planned succession in which, aspreviously announced, Eddie Powell will leave the Company on 20 November 2007after almost eight years as Chief Financial Officer. Jeffrey Michel Iliffe, age 45, is a qualified accountant who worked as acorporate financier in life sciences at Panmure Gordon & Co between 1989 and1996. He then moved into industry, holding a number of financial positions atcompanies including the environmental consultancy Enviros Group Limited and thebiotechnology company Plethora Solutions plc. Prior to joining Abcam as afinancial consultant, he was chief financial officer at St Minver Limited, ane-commerce company that operates online gaming networks. Mr Iliffe's broad financial experience, including acquisitions, businessintegration and investor relations, is expected to be of significant value toAbcam as the Company continues to execute its strategy to become the world'slargest online antibody resource. David Cleevely, Abcam's Chairman, said: "I am delighted to announce theappointment of Jeff Iliffe as Chief Financial Officer and to welcome him toAbcam's Board. I have worked closely with Jeff for the past four months and havebeen very impressed by his energy and ability. His broad financial experience,combined with his specific knowledge of e-commerce, means that he is ideallyqualified to make an important contribution to the ongoing development of theCompany." Jeffrey Iliffe holds or has held directorships in the five years preceding hisappointment at Abcam as follows: Current Directorships Previous DirectorshipsSanford Consulting Limited Enviros Consulting Limited Enviros Group Limited Enviros Limited Enviros Management Services Limited Enviros RIS Limited Merlin General Partner Limited Merlin General Partner II Limited Quantisci Limited Technos Limited There are no further disclosures to be made in accordance with Schedule 2 (g) ofthe AIM rules. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7260 1000Michael MeadeJames Black Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts, and aJapan office in Tokyo. Abcam was admitted to AIM in November 2005 and tradesunder the ticker symbol ABC. The Company produces and distributes its own andthird party produced antibodies to academic and commercial users throughout theworld with product information provided and ordering available through theCompany's website, www.abcam.com. The antibodies are sold under the Abcam brandname. The Company's vision is to build the largest online antibody resource inthe world while also ensuring that the antibodies are of high quality andcommercially viable. Abcam now has an online catalogue of approximately 36,000products, most of which are antibodies, from over 200 suppliers supported byup-to-date and detailed technical data sheets, which are created by the Company.The Company currently employs 140 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock Exchange